NuGen Medical Devices Inc.
NGMDF · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $1 | $0 | $0 | $0 |
| % Growth | 204.7% | 117.5% | 10.7% | – |
| Cost of Goods Sold | $0 | $0 | $1 | $0 |
| Gross Profit | $1 | $0 | -$1 | $0 |
| % Margin | 51.7% | 49.7% | -363.1% | 67% |
| R&D Expenses | $0 | $0 | $0 | $0 |
| G&A Expenses | $5 | $8 | $4 | $2 |
| SG&A Expenses | $5 | $8 | $4 | $8 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $6 |
| Other Operating Expenses | $1 | $1 | $0 | $0 |
| Operating Expenses | $6 | $8 | $4 | $8 |
| Operating Income | -$5 | -$8 | -$5 | -$8 |
| % Margin | -510.7% | -2,428.5% | -3,146.6% | -5,573.1% |
| Other Income/Exp. Net | -$0 | -$1 | -$1 | $1 |
| Pre-Tax Income | -$5 | -$9 | -$6 | -$7 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$5 | -$9 | -$6 | -$7 |
| % Margin | -517.5% | -2,825% | -3,661.1% | -5,163.2% |
| EPS | -0.024 | -0.056 | -0.062 | -0.1 |
| % Growth | 56.3% | 9.9% | 38.1% | – |
| EPS Diluted | -0.024 | -0.056 | -0.062 | -0.1 |
| Weighted Avg Shares Out | 214 | 168 | 90 | 69 |
| Weighted Avg Shares Out Dil | 214 | 168 | 90 | 69 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $2 | $1 | $1 | $1 |
| Depreciation & Amortization | $1 | $1 | $1 | $1 |
| EBITDA | -$3 | -$7 | -$4 | -$5 |
| % Margin | -287.6% | -2,233.3% | -2,767.8% | -3,752.4% |